永安药业
(002365)
| 流通市值：37.84亿 | | | 总市值：45.41亿 |
| 流通股本：2.46亿 | | | 总股本：2.95亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 171,153,602.96 | 838,814,941.7 | 618,715,718.75 | 425,816,581.92 |
| 营业收入 | 171,153,602.96 | 838,814,941.7 | 618,715,718.75 | 425,816,581.92 |
| 二、营业总成本 | 184,150,029.42 | 798,694,169.91 | 583,875,551.55 | 387,989,771.47 |
| 营业成本 | 154,528,544 | 671,116,742.34 | 471,873,467.46 | 313,331,804.97 |
| 税金及附加 | 2,911,591.95 | 9,445,248.41 | 7,622,372.17 | 4,867,721.04 |
| 销售费用 | 4,415,026.54 | 17,277,364.95 | 11,887,942.78 | 7,878,264.03 |
| 管理费用 | 15,216,294.82 | 73,352,046.49 | 68,779,872.24 | 47,990,569.62 |
| 研发费用 | 8,417,652.08 | 36,974,497.81 | 30,378,183.79 | 21,546,474.74 |
| 财务费用 | -1,339,079.97 | -9,471,730.09 | -6,666,286.89 | -7,625,062.93 |
| 其中:利息费用 | 225,867.72 | 585,858.91 | 403,220.03 | 220,968.03 |
| 其中:利息收入 | 280,337.38 | 1,096,356.27 | 1,337,541.88 | 915,789.44 |
| 加:公允价值变动收益 | -2,371,888.97 | 4,431,333.86 | 494,831.48 | 3,773,828.96 |
| 加:投资收益 | 5,189,100.12 | 39,679,131.94 | 28,707,327.09 | 16,718,245.99 |
| 资产处置收益 | 6,694.64 | -326,208.7 | -724,228.32 | -541,060.98 |
| 资产减值损失(新) | - | -18,286,031.52 | -160,682.23 | - |
| 信用减值损失(新) | 1,743,207.89 | -357,213.64 | 239,415.41 | -1,356,018.82 |
| 其他收益 | 818,582.24 | 7,671,601.16 | 5,753,071.67 | 4,677,044.73 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -7,610,730.54 | 72,933,384.89 | 69,149,902.3 | 61,098,850.33 |
| 加:营业外收入 | 28,826.58 | 1,967,662.09 | 544,503.42 | 68,548.71 |
| 减:营业外支出 | 209,048.09 | 4,040,314.61 | 1,069,727.4 | 379,361.67 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -7,790,952.05 | 70,860,732.37 | 68,624,678.32 | 60,788,037.37 |
| 减:所得税费用 | -1,097,010.81 | 11,153,027.59 | 9,824,982.9 | 9,674,869.63 |
| 六、净利润 | -6,693,941.24 | 59,707,704.78 | 58,799,695.42 | 51,113,167.74 |
| 持续经营净利润 | -6,693,941.24 | 59,707,704.78 | 58,799,695.42 | 46,843,119.89 |
| 终止经营净利润 | - | - | - | 4,270,047.85 |
| 归属于母公司股东的净利润 | -4,367,181.24 | 61,766,022.21 | 61,855,243.42 | 52,485,217.27 |
| 少数股东损益 | -2,326,760 | -2,058,317.43 | -3,055,548 | -1,372,049.53 |
| (一)基本每股收益 | -0.02 | 0.21 | 0.21 | 0.18 |
| (二)稀释每股收益 | -0.02 | 0.21 | 0.21 | 0.18 |
| 八、其他综合收益 | -10,617.52 | -1,869,850.36 | -2,054,794.11 | -1,935,157.89 |
| 归属于母公司股东的其他综合收益 | -10,617.52 | -1,869,850.36 | -2,054,794.11 | -1,935,157.89 |
| 九、综合收益总额 | -6,704,558.76 | 57,837,854.42 | 56,744,901.31 | 49,178,009.85 |
| 归属于母公司股东的综合收益总额 | -4,377,798.76 | 59,896,171.85 | 59,800,449.31 | 50,550,059.38 |
| 归属于少数股东的综合收益总额 | -2,326,760 | -2,058,317.43 | -3,055,548 | -1,372,049.53 |
| 公告日期 | 2025-04-29 | 2025-04-10 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |